Phuturdex › Diseases › Hypochondroplasia
Drugs in development · updated 5 November 2026
Hypochondroplasia: drugs in development
What it is
A primary bone dysplasia with micromelia characterized by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.
Source: Orphanet, “Hypochondroplasia” (ORPHA:429), www.orpha.net · licence CC BY 4.0 · Orphadata data of 23 June 2026.
As of 5 November 2026 there are 7 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for hypochondroplasia. 0 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 5 November 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| VosoritideBMN 111, Voxzogo® | III | 4 | NCT07073014 |
| InfigratinibTruseltiq®, Febseltiq® | II–III | 2 | NCT06873035 |
| NavepegritideTransCon CNP, Yuviwel® | III | 1 | NCT07917143 |
Sorted by most advanced phase and number of active trials.
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Endocrine system disease 1,111 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 951 drugs
- Skin and connective tissue diseases 1,519 drugs
- Connective tissue disease 356 drugs
- Metabolic disease 774 drugs
- Nutritional and metabolic diseases 923 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 5 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: C562937 “Hypochondroplasia”. Prevalence: Orphanet.